VantAI is at the forefront of artificial intelligence (AI) research, aiming to “program” protein interactions. Specializing in computational biology and machine learning, VantAI combines these methods with structural proteomics and proximity modulators to accelerate the discovery of new medicines. This proximity modulation method has extensive applications in various diseases through targeting pathways like protein degradation. Mapping these protein interactions will help identify novel therapeutic targets. Through the integration of AI-driven methodologies, VantAI seeks to revolutionize pharmaceutical research, offering promising solutions to complex healthcare challenges. VantAI also collaborates with industry leaders such as Janssen and Bristol Myers Squibb.

VantAI

🔥 Join us for a talk with Jeremy Wohlwend & Gabriele Corso on their recent paper Boltz-1 - a new open source SOTA for 3D structure prediction of biomolecular complexes. 
As always with Michael Bronstein and Bruno Correia

🗓️ When: Fri, Dec 06 - 4p CET/10a ET 
🗒️ Sign-up: https://lnkd.in/e42FCCT9

VantAI Announces Formation of Scientific Advisory Board - GlobeNewswire

VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery - Yahoo Finance

 VantAI Enters Collaboration With Bristol Myers Squibb to... 

 BMS signs $674M biobucks pact with VantAI for molecular glues 

VantAI Inks Second Big Protein Degrader Collab in as Many Weeks - BioSpace

VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery

Roivant gets $200M for major push into protein degradation - Fierce Biotech

VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AI

May 01, 2024VantAI Collaborates With Google Cloud to Harness NVIDIA GPUs for Building Protein Interaction Foundation ModelsVantAI will leverage its proprietary large scale structural data and NVIDIA H100 GPUs on Google Cloud to enable a step-change in accuracy for all-atom protein interaction prediction.

VantAI Launches Neo-1, the First AI Model to Rewire Molecular Interactions by Unifying Structure Prediction and Generation for Therapeutic Design - Yahoo Finance

May 08, 2024VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug DiscoveryVantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery. Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs.

We had the pleasure to have Jeremy Wohlwend and Gabriele Corso give a sneak peak of these on our https://lnkd.in/e4kHMimm lecture a week ago. Recording is now live, link in comments!

July 27, 2023Geometric Deep Learning Pioneer Michael Bronstein joins VantAI as Chief Scientist in Residence to Help Drive Artificial Intelligence Breakthroughs in Drug DiscoveryDr. Bronstein, the DeepMind Professor of AI at Oxford, will help VantAI unlock the potential of induced proximity

Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking ‘the big next step’ after AlphaFold 3 - Endpoints News


              Moving beyond memorisation: Resources for generalisable protein complex prediction
            

 VantAI Inks Second Big Protein Degrader Collab in as Many Weeks 

 Bristol Myers Squibb launches $674M drug discovery partnership with city biotech 

BMS strikes $674M deal with VantAI on AI-driven molecular glues - FirstWord

 Other news to note for March 24, 2025 

Excited to share our talk with José Jiménez Luna and Yu Xie on using deep learning to emulate protein equilibrium ensembles - now live on YouTube! 

Watch here:
https://lnkd.in/eFJ4Bkza


🚀  Don't miss this week's talk with Jeremy Wohlwend and Gabriele Corso, where they will talk about their new model for 3D structure prediction of molecular complexes: Boltz-1.
🗓️ Friday - 4pm CET / 10am ET

BMS signs $674m GenAI drug discovery deal with VantAI - Pharmaceutical Technology

VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence - Business Wire

VantAI looking to rewrite drug discovery rules with Neo-1 system - FirstWord

Roivant Announces Protein Degradation Platform Using VantAI Against Difficult Drug Targets - BioSpace

September 29, 2023VantAI Announces Formation of Scientific Advisory BoardVantAI, a leading company focused on the application of artificial intelligence to drug discovery, today announced its newly formed Scientific Advisory Board (SAB). VantAI’s SAB members are experts in protein design, whole-proteome structural interactomics, and generative AI for small molecule drug design

 BMS, VantAI team up; CRISPR Therapeutics to raise $280M; Ono Pharma's deal with Shattuck Labs 

VantAI Appoints Jae Won Kim as Chief Operating Officer and Chief Financial Officer - citybiz

VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders - GlobeNewswire

🔥 Friday's talk with Zhonglin Cao (NVIDIA), Jay Durairaj (University of Basel), and Daniel Kovtun (VantAI) on P(L)INDER - new benchmarks for protein-protein & protein-ligand interactions is now live on our yt channel (incl. info on upcoming MLSB workshop & slides)

https://lnkd.in/dnxh9v4q

VantAI Unveils Neo-1: The AI Marvel Designing Molecular Glues for Drug Discovery - OpenTools


      
        
      
      

 VantAI Secures Renewed Support from Blueprint Medicines to Chart New Frontiers in Induced Proximity Drug Discovery 

January 9, 2024VantAI Secures Renewed Support from Blueprint Medicines to Chart New Frontiers in Induced Proximity Drug DiscoveryVantAI, a leader in the fields of drug discovery and generative AI, announced today it has entered into an amended and restated collaboration and license agreement with Blueprint Medicines, a leading precision medicine company, to design and advance novel targeted protein degrader therapies to address important areas of medical need.

VantAI Secures Renewed Support from Blueprint Medicines to Chart New Frontiers in Induced Proximity Drug Discovery - Yahoo Finance

📢 Join us next week for a talk with Zhonglin Cao (NVIDIA), Janani Durairaj (University of Basel) & Daniel Kovtun (VantAI) on P(L)INDER: new benchmarks for protein-protein & protein-ligand interactions
Hosted by Michael Bronstein and Bruno Correia

📅Fri, Aug 30 - 5p CET/11a ET
📝Sign-up: https://lnkd.in/e4kHMimm

We are excited to announce the first alpha release of 
💥 peppr - package for evaluation of predicted poses 💥

an open source framework for structural model evaluation

Find out more at peppr.vant.ai/

built on www.biotite-python.org, peppr dramatically simplifies evaluation for structure prediction and de-novo generation tasks.

We built peppr because existing evaluation tools are heavy native binaries with limited cross-platform support and hard to extend. Peppr is built on familiar python and numpy, making it highly extensible without sacrificing speed.

Built on biotite primitives, it also makes interfacing with RDKit and Biotite-based workflows much simpler.

 Vantai, Bristol Myers Squibb collaborate on molecular glues 

VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen - GlobeNewswire

🚀 Happening this week - don't miss this talk on generative modeling for molecular dynamics! 

Drug discovery turned out to be too hard, so VantAI has made the important decision to pivot from molecular glues to regular glues, and today we are thrilled to announce a landmark $800B biobucks deal with Elmer’s.

CTO Luca Naef explains, “When we first prompted Neo-1, our foundation model, we accidentally forgot to specify 'molecular' glues. Instead, it generated formulations for regular glues. Upon testing, we had a eureka moment—the adhesives were outstanding, showcasing the unexpected versatility and power of our AI platform.”

Inspired by our Chief Scientist Michael Bronstein love of horses, all VantAI products will be vegan, leveraging geometric deep learning to revolutionize a space untouched by innovation for decades. “Molecular glues were exciting,” says Bronstein, “but the real opportunity is macro-scale. Our original business plans have, as they say, Склеить ласты—they’ve "had their fins glued together", but luckily everyone’s got something they want stuck together - by accurately predicting polymer interactions and curing dynamics, we’re ushering in a new era of computationally engineered adhesives that outperform conventional products in every measurable way.”

Traditional bonding agents rely on trial-and-error experimentation, leading to unpredictable adhesion strength, durability, and curing times. VantAI's cutting-edge geometric deep learning platform models adhesive interactions at the molecular level, enabling rational, de novo design of glues optimized for specific substrates, environmental conditions, and application methods. This translates to dramatically improved bond reliability, reduced curing times, and tailored mechanical properties.

For inquiries about our innovative adhesive solutions or to explore customized bonding opportunities tailored to your specific needs, please reach out at stickybusiness@vant.ai. Our dedicated team is ready to help you achieve exceptional adhesion outcomes.

 VantAI links up with Bristol Myers on molecular glue drug 

SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff - Endpoints News

Roivant Sciences to absorb Silicon Therapeutics with $450M-plus deal - Fierce Biotech

 VantAI Announces Formation of Scientific Advisory Board 

VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug Discovery

 Predict First: BMS Executives Discuss Company’s AI Approach 

How AI is fighting COVID-19: the companies using intelligent tech to find new drugs - pharmaphorum

LOG IN

April 13, 2022VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with JanssenVantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson

February 28, 2022Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader TherapiesCollaboration will leverage Proteovant's Artificial Intelligence-enhanced targeted protein degradation platform and Blueprint Medicines' small molecule precision medicine capabilities to address medical needs in oncology and hematology

BMS signs $674M biobucks pact with Roivant-backed VantAI for molecular glues - Fierce Biotech

 VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug Discovery 

Geometric Deep Learning Pioneer Michael Bronstein joins - GlobeNewswire

May 22, 2024VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AIVantAI, a company focused on generative AI-enabled drug discovery, today announced the appointments of Dr. Ian Churcher and Dr. Bradley Pentelute to its Scientific Advisory Board (SAB).

Introducing Neo-1: We're thrilled to announce Neo-1—the world's most advanced atomistic foundation model, unifying all-atom structure prediction and de novo generation to decode and design life's molecular structures. Neo-1 employs the latest latent diffusion techniques to reason simultaneously about molecules and their structures, replacing multiple specialist models with one versatile framework.

Design: Neo-1 generates diverse, drug-like small molecules and natural proteins from sequences, properties, or partial inputs. This enables completely novel applications, such as rational molecular glue design directly from sequences.

Decode: Neo-1 achieves state-of-the-art accuracy in all-atom structure prediction, excelling particularly in complex ternary systems.

NeoLink: NeoLink is VantAI's experimental platform using cross-linking mass spectrometry (XLMS) to capture structural constraints across the entire proteome, which Neo-1 integrates into precise atomic models.

Programmability: Highly programmable, Neo-1 supports molecular generation, protein design, structure prediction, and molecular inpainting. Neo-1 can be guided using partial structures, sequences, or desired molecular properties.

Drug Discovery & Optimization: Beyond hit discovery, Neo-1 leverages experimental data, accelerating iterative optimization in drug discovery. Applications already include molecular glues, PROTACs, and antibodies, significantly streamlining the path from computational design to experimental validation.

Learn more: https://www.vant.ai/neo-1

Interested in pioneering the next frontier in biology and AI research? We're hiring—contact recruiting@vant.ai. 

https://lnkd.in/ekF8nfPK

March 21, 2025VantAI Launches Neo-1VantAI launches Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation for therapeutic design.

LEARN MORE

VantAI Launches Neo-1, the First AI Model to Rewire Molecular Interactions by Unifying Structure Prediction and Generation for Therapeutic Design

🔥 Guillaume Huguet and James Vuckovic's talk on FoldFlow-2: Sequence-Augmented SE(3)-Flow Matching For Conditional Protein Backbone Generation is now live on our YouTube channel.

https://lnkd.in/eCj7v3MS 

February 13, 2024VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial IntelligenceVantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.

VantAI Collaborates With Google Cloud to Harness NVIDIA GPUs for Building Protein Interaction Foundation Models

 VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AI 

VantAI Appoints John Cuozzo as Senior Vice President - citybiz

VantAI, BMS Partner to Accelerate Molecular Glue Drug Discovery - Contract Pharma

Blueprint Medicines and VantAI to advance novel therapies with expanded agreement - World Pharmaceutical Frontiers

Less than 1 hour to go!

This $674 Million Deal Aims To Turn Your Body's Garbage Disposal Into A Disease Fighter - Forbes

Vantai and Blueprint Medicines amend agreement to advance novel targeted protein degrader therapies - BioWorld MedTech

BMS, VantAI team up; CRISPR Therapeutics to raise $280M; Ono Pharma's deal with Shattuck Labs - Endpoints News

 VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen 

 This $674 Million Deal Aims To Turn Your Body's Garbage Disposal Into A Disease Fighter 

📢 Join us next week for a talk with Hannes Stärk (MIT) and Bowen Jing (MIT) on MDGEN: Generative modeling of molecular dynamics trajectories
Hosted by Michael Bronstein and Bruno Correia

📅Fri, Nov 15 - 5p CET/11a ET
📝Sign-up: https://lnkd.in/e4kHMimm

May 20, 2025VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug DiscoveryVantAI announced today that it has entered into a second expansion of its collaboration and license agreement with Blueprint Medicines.

Revised Blueprint-VantAI deal turns focus to molecular glues

VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AI - Business Wire

Vantai, Bristol Myers Squibb collaborate on molecular glues - BioWorld MedTech


                VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery
              

April 20, 2022VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein DegradersVantAI will pair its induced proximity platform with BI’s deep early discovery experience to identify targeted protein degraders with enhanced properties for traditionally “undruggable” targets

February 07, 2024VantAI Appoints Jae Won Kim as Chief Operating Officer and Chief Financial OfficerVantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO). Ms. Kim is an experienced finance, corporate development, and operations executive with a strong track record, especially in drug discovery and the induced proximity landscape.

VantAI

Business:

About: